Evgen Pharma plc announced that Toni Hänninen will join the Board of Directors as a Director. The Company also announced that Non-Executive Director, Susan Clement-Davies, will be retiring from the Board. Toni Hänninen was appointed interim CFO in September 2023 and moving onto the Board as a Director.

His appointment is effective from 1 January 2024. Toni was previously CFO at Faron Pharmaceuticals Ltd, an AIM and Nasdaq First North listed clinical stage biopharmaceutical company based in the Finland and the US, developing novel treatments for medical conditions with significant unmet needs. He holds over 20 years of experience in business development and senior finance roles in both public and private companies, working in mature and emerging markets particularly in Europe and the USA where he has accomplished successful fundraises, transactions and fiscal management in the sector.

Toni has an MBA from the Helsinki School of Economics (now Aalto University). Evgen Pharma also confirms that Susan Clement-Davies is retiring from her position as Non-Executive Director on the 31 December 2023 in order to focus on her other board positions. Susan has been on the Evgen Pharma board since 2018 and has provided valuable insight and expertise in that time.